EXAS

NEUTRALM&A

Exact Sciences Corporation

2026-02-25

Price

$103.27

-0.17%

Score11.0Top Tier

Signals5/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

EXAS is currently trading as a 'Special Situation' merger arbitrage play following the February 20, 2026 shareholder approval of its acquisition by Abbott Laboratories (ABT) for $105.00 per share in cash. The stock's behavior—characterized by the 'Quiet Storm' and 'Steady Climb' signals and annualized volatility of just 2.8%—confirms it is effectively pinned to the deal price, trading at a ~1.6% discount ($1.73 spread) to the buyout offer. While the broader 'Risk-On' regime is chasing Alpha in AI/Tech, EXAS acts as a defensive cash proxy; the 'Bullish Divergence' here is simply the market pricing in high deal certainty despite macro noise. The thesis is no longer about earnings growth or Cologuard adoption, but purely about the regulatory timeline to the Q2 2026 closing.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACK

Key Takeaways

**Deal Secured:** Shareholders approved the $105/share Abbott merger on Feb 20, removing the final governance hurdle; the remaining risk is strictly regulatory.
**The Arb Yield:** At $103.27, the stock offers a low-risk ~1.6% capture spread, attractive for institutional cash parking but capped upside.
**Technical Pin:** Price action is structural; the $102.25 support level represents the 'break' price where deal danger would be priced in.

← Back to 2026-02-25 View Full EXAS History →Yahoo Finance &nearr;